StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) company profile

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$34.18−0.87 (-2.48%)

Close on Nov 13, 2026Market cap $7.06BP/E –Yield –

About Immunovant

Biological Products, (No Diagnostic Substances), SIC 2836

Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted treatments for individuals suffering from autoimmune disorders. Its lead candidate is IMVT-1402 (imeroprubart), a fully human monoclonal antibody designed to inhibit the neonatal fragment crystallizable receptor (FcRn) and lower levels of pathogenic immunoglobulin G antibodies. The company develops treatments intended for subcutaneous delivery via an autoinjector across multiple disease areas, including endocrinology, rheumatology, neurology, and dermatology. Its prospective customer and patient base includes individuals affected by conditions such as Graves' disease, difficult-to-treat rheumatoid arthritis, cutaneous lupus erythematosus, and Sjögren's disease.

The company directs its clinical programs toward patient populations across the United States and Europe, having also evaluated IMVT-1402 in clinical trials conducted in New Zealand. The provided excerpt does not disclose the location of Immunovant's corporate headquarters or specific facility counts.

Summary of the business section of Immunovant's latest annual report, written by StockData.

Company profile

Company

Legal name
Immunovant, Inc.
Headquarters
Durham, NC
Address
1000 Park Forty Plaza 27713
Phone
(917) 410-3120
Employees
315, Mar 31, 2026
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
March 31
Auditor
Ernst& Young LLP, Iselin, New Jersey

Stock & identifiers

Ticker
IMVT
Exchange
Nasdaq
IPO date
May 10, 2019
Shares outstanding
207M, Aug 3, 2026
Public float
$1.25B, Sep 30, 2025
Filer category
Large accelerated filer
Stock splits
10-for-3, Feb 14, 2020
SEC CIK
1764013
CUSIP
45258J102
ISIN
US45258J1025
FIGI
BBG00P5MC0Q8
Share class FIGI
BBG00P5MC0R7
EIN
83-2771572

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eric VenkerChief Executive Officer, Director257,075
Peter SalzmannChief Executive Officer, Director1,178,191
Tiago GiraoChief Financial Officer234,192
Jay S. StoutChief Technology Officer198,937
Tuyl Christopher VanChief Legal Officer175,218
Melanie GloriaChief Operating Officer217,060
Michael GeffnerChief Medical Officer217,958
Eva Renee BarnettChief Financial Officer396,774
William L. MaciasChief Medical Officer357,353
Mark S. LevineChief Legal Officer319,228
Atul PandeDirector136,731
Andrew J. FromkinDirector131,400
Robert Graham SusmanDirector36,394
Douglas J. HughesDirector134,653
Jake BauerDirector38,896
Frank TortiDirector1,009,228
Sciences Ltd. RoivantDirector113,317,007
George V. MigauskyDirector157,251

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026
Eric Venker
$20.16M$30.28M$4.09M$155$129
FY2026
Peter Salzmann
$15.33M$12.21M$4.09M$155$129
FY2025$10.73M-$9.32M$4.89M$107$93
FY2024$8.55M$42.52M$3.87M$201$96
FY2023$5.82M$28.19M$1.99M$97$89
FY2022$5.87M-$12.30M$5.63M$34$89

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Eric Venker
Chief Executive Officer
$636.62K$503.35K–$19.01M$8.17K$20.16M–
Tiago Girão
Chief Financial Officer
$455.49K$224.40K$3.63M$3.29M$11.32K$7.62M–
Melanie Gloria
Chief Operating Officer
$495.00K$245.03K$1.16M$1.15M$19.04K$3.07M-45%
Jay Stout
Chief Technology Officer
$495.00K$245.03K$1.16M$1.15M$17.65K$3.07M-23%
Christopher Van Tuyl
Chief Legal Officer and Corporate Secretary
$495.00K$245.03K$771.96K$766.73K$17.06K$2.30M-61%
Peter Salzmann
Former Chief Executive Officer
$39.61K–$8.29M$6.27M$737.64K$15.33M+43%
Eva Renee Barnett
Former Chief Financial Officer
$26.25K–$1.35M$1.46M$387.43K$3.23M-19%
Michael Geffner
Former Chief Medical Officer
$345.52K–$2.56M$2.15M$198.58K$5.25M+30%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
May 10, 2019
Securities offered
10,000,000
Exchange
Nasdaq
First trading day
Jun 21, 2019
First-day close
$9.95
Lock-up ends (est.)
Dec 18, 2019

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 31, 2026, we had 315 full-time permanent employees, primarily in the U.S.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jun 15, 2020DelistingNotice of delisting from exchange (Form 25)
Dec 20, 2019Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 20, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 20, 2019Name changeName changed from Health Sciences Acquisitions Corp to Immunovant, Inc.
Nov 27, 2019Merger voteDefinitive merger proxy statement
May 10, 2019IPOInitial public offering priced (424B4 prospectus)
May 9, 2019ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?